| Stephen M Swan, | |
|
1100 Balsam Ave, Boulder, CO 80304-3404 | |
| (303) 440-2037 | |
| (303) 306-7753 |
| Full Name | Stephen M Swan |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 22 Years |
| Location | 1100 Balsam Ave, Boulder, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326012618 | NPI | - | NPPES |
| 7555344 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | PAL 1917 (Colorado) | Secondary |
| 363A00000X | Physician Assistant | PA.0001917 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Goodland Regional Medical Center | Goodland, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Goodland Regional Medical Center | 3375535263 | 17 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Chiron Corporation has announced that it has reached a settlement with F. Hoffmann-La Roche (Roche) in a dispute over licensing fees and royalties that Chiron had asserted was owed to the company under a licensing agreement related to its U.S. Patent No. 6,531,276 (the "276 Patent").
BioTrends is pleased to announce the publication of a new syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis. This report is the first in a three wave series and is derived from on-line survey responses from 77 rheumatologists and qualitative interviews with 20 rheumatologists.
In a new study, Northwestern Medicine researchers found that patients at high risk for cardiovascular disease (CVD) are more likely to receive a prescription for cholesterol-lowering medication, and to achieve lower long-term cholesterol levels, when doctors use electronic health records (EHRs) to deliver personalized risk assessments via mail.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen M Swan, Po Box 173894, Denver, CO 80217-3894 Ph: (303) 306-7783 | Stephen M Swan, 1100 Balsam Ave, Boulder, CO 80304-3404 Ph: (303) 440-2037 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Chiron Corporation has announced that it has reached a settlement with F. Hoffmann-La Roche (Roche) in a dispute over licensing fees and royalties that Chiron had asserted was owed to the company under a licensing agreement related to its U.S. Patent No. 6,531,276 (the "276 Patent").
BioTrends is pleased to announce the publication of a new syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis. This report is the first in a three wave series and is derived from on-line survey responses from 77 rheumatologists and qualitative interviews with 20 rheumatologists.
In a new study, Northwestern Medicine researchers found that patients at high risk for cardiovascular disease (CVD) are more likely to receive a prescription for cholesterol-lowering medication, and to achieve lower long-term cholesterol levels, when doctors use electronic health records (EHRs) to deliver personalized risk assessments via mail.
› Verified 5 days ago